Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
21,250
-200 (-0.93%)
Jun 27, 2025, 3:30 PM KST
18.06%
Market Cap 262.41B
Revenue (ttm) 22.69B
Net Income (ttm) -3.16B
Shares Out 11.00M
EPS (ttm) -291.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 123,330
Average Volume 314,111
Open 21,500
Previous Close 21,450
Day's Range 20,900 - 21,650
52-Week Range 12,550 - 29,350
Beta n/a
RSI 41.28
Earnings Date Aug 8, 2025

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.